Translocation of TRPV4-PI3Kγ complexes to the plasma membrane drives myofibroblast transdifferentiation
- 12 November 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (607)
- https://doi.org/10.1126/scisignal.aau1533
Abstract
Myofibroblasts are key contributors to pathological fibrotic conditions of several major organs. The transdifferentiation of fibroblasts into myofibroblasts requires both a mechanical signal and transforming growth factor–β (TGF-β) signaling. The cation channel transient receptor potential vanilloid 4 (TRPV4) is a critical mediator of myofibroblast transdifferentiation and in vivo fibrosis through its mechanosensitivity to extracellular matrix stiffness. Here, we showed that TRPV4 promoted the transdifferentiation of human and mouse lung fibroblasts through its interaction with phosphoinositide 3-kinase γ (PI3Kγ), forming nanomolar-affinity, intracellular TRPV4-PI3Kγ complexes. TGF-β induced the recruitment of TRPV4-PI3Kγ complexes to the plasma membrane and increased the activities of both TRPV4 and PI3Kγ. Using gain- and loss-of-function approaches, we showed that both TRPV4 and PI3Kγ were required for myofibroblast transdifferentiation as assessed by the increased production of α-smooth muscle actin and its incorporation into stress fibers, cytoskeletal changes, collagen-1 production, and contractile force. Expression of various mutant forms of the PI3Kγ catalytic subunit (p110γ) in cells lacking PI3Kγ revealed that only the noncatalytic, amino-terminal domain of p110γ was necessary and sufficient for TGF-β–induced TRPV4 plasma membrane recruitment and myofibroblast transdifferentiation. These data suggest that TGF-β stimulates a noncanonical scaffolding action of PI3Kγ, which recruits TRPV4-PI3Kγ complexes to the plasma membrane, thereby increasing myofibroblast transdifferentiation. Given that both TRPV4 and PI3Kγ have pleiotropic actions, targeting the interaction between them could provide a specific therapeutic approach for inhibiting myofibroblast transdifferentiation.Keywords
Funding Information
- NIH Office of the Director (HL119792)
- NIH Office of the Director (HL133721)
- NIH Office of the Director (HL089473)
- NIH Office of the Director (HL132079)
- NIH Office of the Director (HL133380)
This publication has 68 references indexed in Scilit:
- Recent Developments in Myofibroblast Biology: Paradigms for Connective Tissue RemodelingThe American Journal of Pathology, 2012
- Loss of PPARγ expression by fibroblasts enhances dermal wound closureFibrogenesis & Tissue Repair, 2012
- Matrix rigidity regulates a switch between TGF-β1–induced apoptosis and epithelial–mesenchymal transitionMolecular Biology of the Cell, 2012
- A Multiwell Platform for Studying Stiffness-Dependent Cell BiologyPLOS ONE, 2011
- Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γMolecular Cell, 2011
- Importance of Non-Selective Cation Channel TRPV4 Interaction with Cytoskeleton and Their Reciprocal Regulations in Cultured CellsPLOS ONE, 2010
- Mechanotransduction gone awryNature Reviews Molecular Cell Biology, 2009
- Prostaglandin E2 Inhibits Specific Lung Fibroblast Functions via Selective Actions of PKA and Epac-1American Journal of Respiratory Cell and Molecular Biology, 2008
- Intracellular trafficking of TRP channelsCell Calcium, 2007
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002